RxDoctor Payments Data

Jyoti Mehta, MD

Internal Medicine · Williamsburg, OHNPI 1932170933

Payments from drug & device makers

$689in general payments, 2019–2025

Across 11 payments — averaging $62.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$230
  • Acadia Pharmaceuticals Inc$120
  • AstraZeneca$97
  • Teleflex LLC$88
  • Johnson & Johnson$50
  • Lantheus Medical Imaging, Inc.$28
  • plus $76 from 4 others

What the payments were for

  • Food & beverage$689100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$689 in reported general payments places this provider in the 70th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$93,309
Medicare patients
281
Services billed
1,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban886$363,381
IngrezzaValbenazine Tosylate49$196,766
TrulicityDulaglutide151$134,352
FarxigaDapagliflozin Propanediol223$110,126
OzempicSemaglutide97$109,088
JardianceEmpagliflozin203$107,890
Trelegy ElliptaFluticasone/Umeclidin/Vilanter113$78,846
EntrestoSacubitril/Valsartan182$69,272
XareltoRivaroxaban133$53,048
XifaxanRifaximin18$38,336
Invega SustennaPaliperidone Palmitate15$34,977
TivicayDolutegravir Sodium26$28,738
Atorvastatin Calcium1,886$27,673
DescovyEmtricitabine/Tenofov Alafenam12$27,656
Breo ElliptaFluticasone/Vilanterol57$24,503

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$22$196,76649 claims
AstraZenecaFarxiga, Breztri Aerosphere$97$122,195243 claims
Johnson & JohnsonXarelto, Invega Sustenna, Procrit$50$106,193179 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Williamsburg

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →